Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0
μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin
in the treatment of chronic hepatitis C, and to determine therapeutic dose of Algeron.